Catalytic anticancer metallodrugs active at low doses could minimize side-effects, introduce novel mechanisms of action that combat resistance and widen the spectrum of anticancer-drug activity.

A catalyst that helps convert alkynes into alkenes could offer a more efficient and greener way to achieve the tricky industrial transformation (ACS Catal. 2024, DOI: 10.1021/acscatal.4c00310 ...